Who owns BIOCRYST PHARMACEUTICALS INC (BCRX)? Elite investor 13F holders

5 tracked elite investors reported holding BIOCRYST PHARMACEUTICALS INC as of 2026-06-30, including Renaissance Technologies LLC, Bridgewater Associates, D.E. Shaw, Gotham Asset Management, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCBIOCRYST PHARMACEUTICALS INCSHARE2026-06-302026-08-13 00:00:0025302900.00 USD2530290.000000SharesaddOriginal filing
Bridgewater AssociatesBIOCRYST PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:004910570.00 USD491057.000000SharesreduceOriginal filing
D.E. ShawBIOCRYST PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:004085290.00 USD408529.000000SharesaddOriginal filing
Gotham Asset ManagementBIOCRYST PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:001564210.00 USD156421.000000SharesreduceOriginal filing
Tudor InvestmentBIOCRYST PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:001951280.00 USD195128.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown